Priveterra Acquisition Corp. (PMGM) Secures $20M Commitment for AEON Biopharma Deal
by Marlena Haddad on 2023-01-10 at 8:56am

Priveterra Acquisition Corp. (NASDAQ:PMGM) and its biopharmaceutical target, AEON Biopharma, announced this morning that they have secured an additional $20 million in commitments from existing investors in connection to its business combination.

The SPAC brought about $276 million into the deal through its current trust but aside from today’s funding, it has not yet supplemented this with other committed sources of capital. Priveterra must maintain at least $45 million in cash available in order for the deal to close, which means the SPAC potentially still needs to secure an additional $25 million in capital.

Under the terms of the commitments, the issued security is to be exchanged or converted into Class A common stock of the combined company once the proposed merger is completed, and is expected to fund concurrently with or immediately prior to the closing of the deal.

PMGM announced its $201.8 million business combination with drug developer AEON on December 13, 2022. Irvine, California-based AEON is working on an injection-based migraine treatment to compete with Botox for chronic and frequent sufferers.

AEON Biopharma also announced in December the completion of patient enrollment in the Phase 2 study of ABP-450 for the preventive treatment of episodic migraine. The company expects to announce top-line data from the study in the second half of 2023.


Recent Posts
by Kristi Marvin on 2024-04-20 at 11:45am

Terms Tracker for the Week Ending April 19, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. Passover and school spring break starts next week, which most likely means a slowdown in SPAC filing activity. Although Churchill IX is now rumored to...

by Nicholas Alan Clayton on 2024-04-19 at 3:00pm

Despite a week of general pull-backs in the market, fintech firm Ibotta (NYSE:IBTA) nonetheless took the dive and had a good week debuting via a traditional IPO in the choppy waters. The company, which provides app-based consumer cashback discounts on purchases, priced its IPO at $88, above its proposed range of $76 to $84, and...

by Nicholas Alan Clayton on 2024-04-19 at 7:53am

At the SPAC of Dawn Happy Friday! SPACInsider has unveiled new presets on SPAC Performance accessible via the Data drop-down to easily sort for the highest and lowest performing active SPACs and de-SPACs. On the de-SPAC side, Vertiv (NYSE:VRT) continues to be well ahead of the pack, logging a 710% return by share price adjusted...

by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...


Copyright © 2023 SPACInsider, Inc. All Rights Reserved